FDA Grants Priority Review Designation for Heron Therapeutics' NDA for HTX-011, a Non-Opioid for Postoperative Pain Management
FDA Assigned PDUFA Goal Date of April 30, 2019
FDA Not Currently Planning Advisory Committee Meeting for NDA
SAN DIEGO, Dec. 31, 2018 -- (Healthcare Sales & Marketing Network) -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnol... Biopharmaceuticals, Surgery, FDA Heron Therapeutics, postoperative pain, bupivacaine, meloxicam
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Grants | Marketing | Meloxicam | Mobic | Pain | Pain Management | Pharmaceuticals